Skip to content

Study · Not a test of the peptide alone · 2019

5 results

Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System.

Qi P, Bu R, Zhang H, Yin J, Chen J, Zhang A, Gou J, Yin T, Zhang Y, He H, Wang P, Tang X, Wang Y

Molecular pharmaceutics10 Jul 2019Cited by 26 (Europe PMC)

PMID31251642 (opens in a new tab)DOI10.1021/acs.molpharmaceut.9b00344 (opens in a new tab)PepBankPUB-31251642
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Goserelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Goserelin.

  1. 01AnimalNot a test of Goserelin aloneAnimal study (in vivo)Other

    In vivo, goserelin hydrogel PLGA microspheres provided a prolonged administration interval of 49 days.

    In plain wordsIn the in-vivo test, goserelin hydrogel microspheres provided an administration interval of 49 days.

    Peptide
    Goserelin
    Outcome
    Not applicableAdministration interval
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Under the interaction of hydrogel and PLGA depots, high encapsulation efficiency (94.16%) and low burst release (less than 2%) were achieved, along with the accompanying prolonged administration interval (49 days);
    1 context sentence
    Summary · context
    Here, the PLGA microsphere containing Poloxamer hydrogel loaded with ∼15% (w/w) GOS was prepared by double-emulsion-solvent evaporation method and evaluated in terms of microscopic structure, physicochemical properties, and release manner in vitro and in vivo.

    In this study, Goserelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Goserelin.

  2. 02AnimalNot a test of Goserelin aloneAnimal study (in vivo)Pharmacokinetics

    In vivo, goserelin hydrogel PLGA microspheres had relative bioavailability 9.36-fold higher than the Zoladex implant.

    In plain wordsIn the in-vivo test, goserelin hydrogel microspheres had 9.36-fold higher relative bioavailability than the Zoladex implant.

    Peptide
    Goserelin
    Outcome
    IncreaseRelative bioavailability
    Study

    n: not reported in source

    Comparator
    Zoladex implant
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    an enhanced relative bioavailability 9.36-fold higher than that of Zoladex implant was also observed.
    1 context sentence
    Summary · context
    Here, the PLGA microsphere containing Poloxamer hydrogel loaded with ∼15% (w/w) GOS was prepared by double-emulsion-solvent evaporation method and evaluated in terms of microscopic structure, physicochemical properties, and release manner in vitro and in vivo.

    In this study, Goserelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Goserelin.

  3. 03LabNot a test of Goserelin aloneIn vitro (cell-free)Other

    In lab tests, goserelin hydrogel PLGA microspheres achieved 94.16% encapsulation efficiency.

    In plain wordsIn lab tests, goserelin hydrogel microspheres achieved 94.16% encapsulation efficiency.

    Peptide
    Goserelin
    Outcome
    Not applicableEncapsulation efficiency
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Under the interaction of hydrogel and PLGA depots, high encapsulation efficiency (94.16%) and low burst release (less than 2%) were achieved,
    1 context sentence
    Summary · context
    Here, the PLGA microsphere containing Poloxamer hydrogel loaded with ∼15% (w/w) GOS was prepared by double-emulsion-solvent evaporation method and evaluated in terms of microscopic structure, physicochemical properties, and release manner in vitro and in vivo.

    In this study, Goserelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Goserelin.

  4. 04LabNot a test of Goserelin aloneIn vitro (cell-free)Other

    In lab tests, goserelin hydrogel PLGA microspheres achieved burst release below 2%.

    In plain wordsIn lab tests, goserelin hydrogel microspheres released less than 2% initially.

    Peptide
    Goserelin
    Outcome
    Not applicableBurst release
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Under the interaction of hydrogel and PLGA depots, high encapsulation efficiency (94.16%) and low burst release (less than 2%) were achieved,
    1 context sentence
    Summary · context
    Here, the PLGA microsphere containing Poloxamer hydrogel loaded with ∼15% (w/w) GOS was prepared by double-emulsion-solvent evaporation method and evaluated in terms of microscopic structure, physicochemical properties, and release manner in vitro and in vivo.

    In this study, Goserelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Goserelin.

  5. 05LabNot a test of Goserelin aloneIn vitro (cell-free)Other

    In lab tests, adding 1-5% acetic acid to goserelin microspheres shortened release lag time to 6 days.

    In plain wordsIn lab tests, adding acetic acid shortened goserelin microsphere release lag time compared with the formulation without added acid.

    Peptide
    Goserelin
    Outcome
    DecreaseRelease lag time
    Study

    n: not reported in source

    Comparator
    Formulation without added acetic acid
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Also, by addition of 1-5% acetic acid, the lag time was shortened to 6 days.
    1 context sentence
    Summary · context
    Here, the PLGA microsphere containing Poloxamer hydrogel loaded with ∼15% (w/w) GOS was prepared by double-emulsion-solvent evaporation method and evaluated in terms of microscopic structure, physicochemical properties, and release manner in vitro and in vivo.

    In this study, Goserelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Goserelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.